Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr;36(4):625-626.
doi: 10.1002/jbmr.4280. Epub 2021 Mar 19.

Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody

Michael P Whyte  1   2
Affiliations
Free article
Editorial

Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody

Michael P Whyte. J Bone Miner Res. 2021 Apr.
Free article
No abstract available

PubMed Disclaimer

Comment on

  • Burosumab for the Treatment of Tumor-Induced Osteomalacia.
    Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Jan de Beur SM, et al. J Bone Miner Res. 2021 Apr;36(4):627-635. doi: 10.1002/jbmr.4233. Epub 2021 Jan 12. J Bone Miner Res. 2021. PMID: 33338281 Free PMC article. Clinical Trial.

References

    1. Jan de Beur SM, Miller PD, Weber TJ, et al. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 2021. Epub ahead of print. https://doi.org/10.1002/jbmr.4233.
    1. Ovejero D, Lim YH, Boyce AM, et al. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos Int. 2016;12:3615-3626.
    1. Smith P, Bayliss S, Shinawi M, et al. First report of burosumab (anti-FGF23 monoclonal antibody) for rickets complicating HRAS-associated cutaneous skeletal hypophosphatemia syndrome (abstract). J Bone Miner Res. 2019;34(Suppl 1):75.
    1. Mumm S, Huskey M, Cajic A, et al. PHEX 3'-UTR mutation c.*231A>G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets. J Bone Miner Res. 2015;30:137-143.
    1. Smith PS, Gottesman GS, Zhang F, et al. X-linked hypophosphatemia: uniquely mild disease associated with PHEX 3'-UTR mutation c.*231A>G (a retrospective, case-control study). J Bone Miner Res. 2020;35:920-931.

Supplementary concepts

LinkOut - more resources